

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61N 1/39		A1	(11) International Publication Number: WO 97/06854 (43) International Publication Date: 27 February 1997 (27.02.97)
(21) International Application Number: PCT/US96/13016		(81) Designated States: CA, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 9 August 1996 (09.08.96)		Published <i>With international search report.</i>	
(30) Priority Data: 08/513,685 11 August 1995 (11.08.95) US			
(71) Applicant: CARDIAC PACEMAKERS, INC. [US/US]; 4100 Hamline Avenue North, St. Paul, MN 55112-5798 (US).			
(72) Inventors: HSU, William; 8631 Yalta Street N.E., Circle Pines, MN 55014 (US). LIN, Yayun; 1866 Huron Avenue, St. Paul, MN 55113 (US).			
(74) Agent: SLIFER, Russell, D.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).			

(54) Title: DEFIBRILLATION BY COORDINATION WITH COARSE VF COMPLEXES



(57) Abstract

A method and system for ventricular defibrillation by coordinating the delivery of defibrillation shocks with sensed ventricular fibrillation complexes in a way which improves the probability of success of the defibrillation shock. Ventricular electrical activity is monitored during VF to detect coarse VF complexes. The defibrillation shock is delivered in coordination with the occurrence of coarse VF complexes, and specifically to occur on the upstroke portion thereof, for optimal probability of success. Preferably, DF shock is delivered on the nth occurring coarse VF complex, wherein n is equal to or greater than 2 and less than or equal to about 9.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

DEFIBRILLATION BY COORDINATION WITH COARSE VF COMPLEXES

5

Field of the Invention

This invention pertains to the field of treatment of ventricular fibrillation by the delivery of electric defibrillation shocks. In particular, the invention pertains to a method and system for coordinating the delivery of defibrillation 10 shocks with sensed ventricular fibrillation complexes in a way which improves the probability of success of the defibrillation shock.

Background of the Prior Art

Electric shock defibrillation is a proven technique of treatment of the serious and immediately life-threatening condition of ventricular fibrillation 15 (VF). For patients known to be at risk, an implantable defibrillator may be used. Such devices contain an energy source, an electrode lead system in contact in the heart, a sensing system to detect the onset of fibrillation, and a pulse generator for delivering the defibrillation (DF) shock. Often they are combined with a pacemaker function in the same device.

20 Existing devices are generally designed or programmed to deliver a shock or series of shocks at a fixed interval or intervals following the detection of the fibrillation, unless fibrillation spontaneously terminates on its own first, or until recovery is achieved, as evidenced by the resumption of normal ventricular rhythm. The amount of energy to be delivered in a shock must be carefully 25 chosen. If too small, it may not be successful in terminating the fibrillation. On the other hand, the shock must not be too large, from physiological considerations, and also in consideration of the limited energy storage in an implanted device.

It is also known in the treatment of tachyarrhythmia to use an implantable 30 atrial defibrillator to deliver pulses of defibrillating energy to the atria synchronized with sensed R waves of the ventricle. However, in the case of VF,

there is not an R wave to synchronize to, so the DF shock must be delivered asynchronously.

It is known that ventricular electrical signals during fibrillation may exhibit a pattern, known as "fine VF," characterized by relatively low signal 5 amplitude and lack of organized features; and they may also exhibit a pattern known as "coarse VF," subjectively characterized by intervals of higher amplitude, which may repeat, separated by fine VF intervals. It has also been suspected that it is easier to defibrillate coarse VF than fine VF. Because of this, previous works have suggested the possibility of timing of DF shocks to features 10 of the VF waveforms as a way to improve DF efficacy. However, it has not been clear from such prior works, which features are important, and how to detect and coordinate to them.

One experimenter retrospectively noted diastolic periods in the monophasic action potential (MAP) tracings, and suggested these periods were 15 more conducive to defibrillation. Another retrospectively observed that some subthreshold defibrillations which were successful had a fixed timing relationship with a bipolar sensing signal in the right ventricle of dogs. However, another study examined spatial coherence in VF on surface of heart using epicardial sensing electrodes, and concluded that coarseness and fineness of VF 20 was mainly due to lead orientation, and not to the degree of organization of electrical activity as measured. Therefore, there appears to be no firm correlation per se recognized in the prior art between DF shock timing and VF features, especially one that may be successfully applied prospectively. One recent study retrospectively examined the correlation between the voltages measured on the 25 surface leads and the energy required to defibrillate dogs instrumented with epicardial patches. Some reduction in energy requirements was found with defibrillation shocks that happened at places where measured voltages were "high."

It is clear that while a number of investigators have pointed to the 30 possibility of using VF waveform features as a guide to delivering DF shocks, there are problems to be solved in the practical and effective prospective

detection of VF features, and the determination of which features thereof are significant, in terms of coordination of DF shocks, for maximizing efficacy.

Summary of the Invention

As explained in detail below, we have provided an improved method and system for detecting an optimal timing for the delivery of shocks, such that the shocks delivered have an improved probability of success in terminating the fibrillation. This improved efficacy provides important medical advantages to the patient, both in the greater probability of success of individual shocks, and also in the reduction in pulse energy and number of shocks needed to defibrillate. The method and system of the invention is based in part on the detection of characteristics of coarse VF complexes which may exist during fibrillation, and the coordination of DF shocks with portions of those complexes.

To overcome the problems in the prior art, the present invention provides an improved method and system for detecting coarse VF complexes, and for coordinating the delivery of DF shocks.

According to one feature of the invention, ventricular electrical activity is monitored during a period of ventricular fibrillation, and the occurrence of coarse VF complexes is detected. A favorable instant of time for delivery of a DF shock is selected when the magnitude or absolute value of the monitored VF signal reaches a predetermined value during a period of increasing signal. In this way the DF shock may be coordinated with the upslope portion of a VF complex.

According to another feature of the invention, the nth occurring coarse VF complex is selected for the coordinated DF shock, where n is equal to 2 or more, and less than or equal to about 9. As a practical matter, the coordinated DF shock should be delivered prior to that count, because of the time element.

According to another aspect of the invention, an improved defibrillator system includes a lead system for placement in electrical contact with the ventricle of the heart and a sensing system attached to lead for monitoring ventricular electrical activity. The sensing system detects the occurrence of VF, and during VF, also detects coarse VF complexes. The system includes a

controlled DF pulse generator for delivering DF shocks to the lead system to the ventricle. A control system for controlling the pulse generator, operates in responsive to the sensing system and triggers the DF pulse generator to deliver a DF shock when the sensed VF complex increases to a predetermined value with 5 a positive rate of change. In this manner, the DF shock is coordinated with the upslope of a VF complex, which we have found will substantially improve the probability of success of the DF shock.

According to a preferred form of this system, control system is operative to count the occurrence of VF complexes, and to trigger delivery of a DF shock 10 coordinated with the nth coarse VF complex, where n is equal to or greater than 2 and less than or equal to about 9. If success is not achieved with coordinated DF shocks, the system switches to asynchronous shocks.

These and other features and advantages of the invention will become apparent from the following description of the preferred embodiments of the 15 invention.

Brief Description of the Drawing

Figure 1 is a block diagram of an implantable defibrillator/ pacemaker of the type with which the present invention may be implemented, including a diagrammatic representation of a lead system placed in a heart;

20 Figure 2 is a flow chart illustrating a mode of operation of the defibrillator/pacemaker of Figure 1 in detecting tachyarrhythmia and VF;

Figure 3 is a waveform of a morphology signal from a heart in VF;

Figure 4 is a flow chart illustrating the computation of Standard Amplitude of Morphology (SAM) by the system;

25 Figure 5 is a flow chart illustrating the operation of the invention for delivering DF shocks coordinated with a VF feature; and

Figure 6 is a waveform of a morphology signal from a heart showing fine VF and coarse VF complexes, and illustrating the delivery of the DF shock coordinated with a VF feature.

Description of the Preferred Embodiment

The preferred embodiment of the invention is illustrated herein as included in an implantable heart defibrillator/pacemaker, which may include numerous pacing modes as is generally known in the art. The system and method 5 of the invention could also be implemented in an external defibrillator/monitor.

In Figure 1, defibrillator/pacemaker 10 is shown in block diagram form. It includes terminals, labeled with reference numbers 11, 12, 13, and 14, for connection to a lead system 20. Lead system 20 is preferably an endocardial lead, although other types could also be used within the scope of the invention.

10 An endocardial lead is adapted for placement in the right ventricle. The lead system includes a number of electrodes or electrical contacts. The tip electrode 21 is at the distal end of the lead system, and connects electrically through a conductor provided in the lead, for connection to terminal 11. Lead system 20 also includes an RV coil electrode 22 space near the distal end for placement in

15 the right ventricle, and this RV coil electrode connects through internal conductors in the lead and is connected both to terminals 12 and 13. The lead system 20 also includes an SVC electrode 23, positioned a distance back from the distal end of the electrode as indicated. The SVC electrode is connected to terminal 14.

20 The defibrillator/pacemaker 10 is a programmable microprocessor-based system, with a microprocessor indicated by reference number 30. Microprocessor 30 operates in conjunction with a memory 32, which contains parameters for various pacing and sensing modes. Microprocessor 30 includes means for communicating with an internal controller, in the form of an RF

25 receiver/transmitter 34. This includes a wire loop antenna 35, whereby it may receive and transmit signals to and from an external controller 36. In this manner, programming inputs can be applied to the microprocessor of the defibrillator/pacemaker after implant, and stored data on the operation of the system in response to patient needs can be read out for medical and analysis.

In the defibrillator/pacemaker of Figure 1, the tip and RV coil, connected through leads 11 and 12, are applied to a sense amplifier 15, whose output is shown connected to an R wave detector 16. These components serve to amplify and sense the QRS wave of the heart, and apply signals indicative thereof to a 5 microprocessor 30. Among other things, microprocessor 30 responds to the R wave detector 16, and provides pacing signals to a pace output circuit 17, as needed according to the programmed pacing mode. Output circuit 17 provides output pacing signals to terminals 11 and 12, which connect as previously indicated to the tip and RV coil electrodes, for normal pacing.

10 The DF portion of the defibrillator/pacemaker Figure 1 includes a high energy output pulse generator 40, which operates under the control of microprocessor 30, as indicated. Pulse generator 40 is connected to terminals 13 and 14, which connect to the RV coil and SVC as previously mentioned. In this manner, DF shocks can be provided through the endocardial lead system 20 for 15 defibrillation when called for by the microprocessor, and specifically the software implementation of control algorithms.

Figure 2 illustrates overall modes of operation of the system. In paced operation, the system operates under programmed control to monitor heart beats occurring in the patient's heart. This is indicated by block 100 in Figure 2. As is 20 generally known in the art, such monitoring is accomplished through the sense amp and R wave detector, elements 15 and 16 in Figure 1, and microprocessor control. Pacing may be administered as needed, depending upon the type of pacing functions provided in the defibrillator/pacemaker.

Decision block 102 tests whether a tachyarrhythmia has been detected. 25 This is done through analysis of electrical signals from the heart under control of the microprocessor and its stored program. If such condition is not detected, control branches via path 103 back to the heart beat monitor block 100, and the process continually repeats.

If, however, a tachycardia arrhythmia condition is detected at decision 30 block 102, control passes via path 105 to decision block 106, which tests for VF,

through analysis of heart signals as is known in the art. If VF is not detected, control branches to block 108 for VT therapies, as is known in the art.

If at block 106, VF is detected, control branches to the VF therapies of Figs. 4 and 5, which include coordinated DF shocks according to the present 5 invention, as described in greater detail below.

Figure 3 illustrates a morphology signal such as would be detected by sensing amp 18, from the signal appearing across the RV coil-SVC in an endocardial lead. For other types of lead systems, similar or corresponding signals would be present. In Figure 3, the wave form is the voltage signal at the 10 sense amp 18. The vertical axis represents amplitude, and the horizontal axis represents time. As used herein, the heart (morphology) signals are represented as what is considered as normal polarity of signals from the heart. Thus, references to increasing signal, positive slope, or upslope, are all with reference to normal polarity. Reversing the polarity of the leads would cause reversal of 15 the polarity of the signal, in which case a corresponding reversal of positive slope to negative slope. If the polarity of sensing is changed, the system could coordinate DF shocks on negative-going signals, but the data to date suggests this might not be as effective. Alternatively, the absolute value of the sensed signal could be used, which would correspond to either positive or negative 20 polarity signals. For purposes of the preferred embodiment, positive or normal polarity will be assumed.

In Figure 3 Zones F1 and F2 show regions of fine VF. Zones C1 and C2 show coarse VF complexes. Within complex C1, a single peak feature of the complex is indicated by reference number 50. The difference in amplitude 25 between the amplitude extremes, 52, 51, indicates the peak-to-peak amplitude calculation which is used as a part of the method of the invention.

In Figure 4, the symbol "1" in the circle is the link from Fig. 2. Upon occurrence or detection of a VF condition, the Standard Amplitude of Morphology (SAM) is computed for a five-second interval. The five seconds is 30 programmable, and a different value may be used. At block 120, which is reached after a VF has been detected in Figure 2, a time is initialized at a starting

or zero point. Flow in branches to step 122, where the SAM is computed, based upon peak-to-peak value readings, as indicated in Figure 3. Preferably, this is accomplished by continually taking samples of the morphology signals and comparing them with previously obtained samples. When such comparison

5 shows a trend reversing, i.e., from decreasing to increasing, or from increasing to decreasing in value, a bottom or top, i.e., a peak, negative or positive, has been reached. Such peak values are then stored for comparison with other peak values as part of the SAM calculation. For each peak occurring in a complex, the high and low values, and hence the peak-to-peak values, are calculated and stored.

10 Flow then proceeds to decision block 124, where the time for this five-second interval is tested. If the five seconds (or other programmable interval) has not passed, flow branches back via path 125 to the computation block 122, and computation detection of peaks and computation of peak-to-peak value continues. If, however, the time has exceeded or equaled the five-second set

15 interval, control passes to block 126. At this point, the SAM is calculated, as being the average of the five largest peak-to-peak measurements during the five-second interval in Figure 4. This is done through recall, comparison, and calculation based upon the stored peak values.

Figure 5 shows the operation of the system for delivering coordinated DF

20 shocks based on sensed VF complex features. The start of Figure 5 is reached from the flow chart of Figure 4. At step 140 n (the count for CMC discussed below) is set to zero, the waiting period is initialized, and the waiting period timer is started. This defines the time period during which coordinated DF shocks may be attempted, and after which the system will switch to

25 asynchronous DF shocks. This time period is preferably programmable as one of the programming parameters for the defibrillator/pacemaker 10 microprocessor. This time period must be kept within reasonable physiological limits, before going to asynchronous mode. For example, a period of 10 seconds may be appropriate. Decision block 142, which potentially is looped through multiple

30 times, tests whether the waiting time limit programmed for coordinated DF shocks has passed. If not, control passes to step 144, where the amplitude of the

morphology signal for the present or current point is taken by sense amp 18. This could be done by hardware or software in analyzer 19, part of which could also be done by software in microprocessor 30.

The amplitude of the current point is compared to the previously

5 computed value of SAM, at step 144. If it has a peak-to-peak amplitude greater than or equal to 50% of SAM, it is identified as a Candidate Morphology Complex (CMC), and a count of CMC is incremented by one.

The CMC count n is tested at step 146. If the count is equal to or above the programmed number (which is 2, in Figure 5, but which could be changed by

10 programming the system), control passes to step 148. If not, control returns to path 147 and the start of the sequence.

At step 148 the system tests whether the current point is on an upslope, i.e. has a positive slope. This is done by comparing the amplitude of the current point to the amplitude of the previous point, to determine the trend.

15 Step 150 then tests whether the current point is at greater than 50% of the SAM value, and has a positive slope. If either of these is not met, then control branches to path 147, to repeat the loop. If both of these conditions are met, then control passes to step 152. Also, if the waiting period had timed out in step 142, without finding the required conditions for coordinated DF shocking, then

20 control would have passed via path 143 to step 152, also.

At step 152, the system tests whether the stored energy in the high energy output 40 has reached the pre-programmed level. It may take several seconds to do so, depending on the set level and the battery condition. If the energy level has not been reached, control passes via 147 to loop again. After the energy level

25 has been reached at step 152, control passes to step 160, which causes the DF pulse generator 40 to deliver the DF shock.

This is illustrated in the waveform of Figure 6, which is a morphology signal similar to Figure 3. The zone labeled F is a area of fine VF, and the zone C is a coarse VF complex. As the VF is occurring in real time, the system is

30 sensing and monitoring the morphology signal. After the first major peak indicated the system has determined that a peak of a possible coarse VF complex

has occurred, and the count is incremented at the peak "n=2". Assume, as is the case in Figure 6, that it is in fact the start of a VF complex. The second peak "n=2" is counted as 2. On the next upslope, as the amplitude passes 50% of the Standard Amplitude of Morphology (SAM), on a CMC peak count of 2 or more, 5 and with a positive slope, and if there is sufficient energy at step 152, the decision is made based on these criteria to deliver the DF shock. The microprocessor 30 and pulse generator 40 then deliver the shock shortly thereafter based on this decision. The DF shock is indicated at line 162.

Following the delivery of the DF shock, the sensing circuits of the 10 defibrillator/pacemaker check to see whether the shock was successful, that is, whether the VF has stopped. This is represented by a return to point "0" at the start of Figure 2. If not successful, and if VF continues, this is detected in Fig. 2, and control passes again to Fig. 5 to repeat the VF therapy. The waiting period (steps 140, 142) for the second or higher passes can preferably be by-passed (or 15 at least separately programmed from the first pass). Then if the first shock fails, the process of sensing and coordination for delivery for a second shock can begin immediately.

We Claim:

1. A method of treating ventricular fibrillation, comprising the steps of:
 - a) monitoring a signal representative of ventricular electrical activity during a period of ventricular fibrillation;
 - b) detecting in the monitored signal, the occurrence of coarse VF complexes;
 - c) analyzing coarse VF to determine upslope; and
 - d) delivering a DF shock during the upslope portion of a complex.
- 10 2. A method according to claim 1, including the step of counting occurrences of coarse VF complexes, and coordinating the delivery of the DF shock with the upslope of a predetermined numbered occurrence of coarse VF complex.
- 15 3. The method of claim 1 wherein the step of monitoring comprises monitoring the morphology signal, across proximal and distal shocking coils of an endocardial lead, and wherein the step of delivering a DF shock includes applying a pulse of electrical energy to the endocardial lead.
- 20 4. The method of claim 1 wherein the steps of detecting and analyzing the occurrence of a coarse VF complex includes sensing when the amplitude of the VF signal is greater than a predetermined value with a positive slope or rate of change.
- 25 5. The method of claim 1 wherein the step of delivering a DF shock includes timing the shock based on when the amplitude of the VF signal is greater than a predetermined value and has a positive slope or rate of change.

6. A method of treating ventricular fibrillation, comprising the steps of:

- monitoring a signal representative of ventricular electrical activity during a period of ventricular fibrillation;
- detecting and counting the occurrence of coarse VF complexes;

5 and

- delivering a DF shock during the nth counted complex, where n is a number greater than or equal to 2 and less than or equal to about 9.

7. The method of claim 6 wherein the step of monitoring comprises

10 monitoring the morphology signal, between proximal and distal shocking coils, of an endocardial lead, and wherein the step of delivering a DF shock includes applying a pulse of electrical energy to the endocardial lead.

8. The method of claim 6 wherein the step of detecting the occurrence of a

15 coarse VF complex includes sensing when the amplitude of the VF signal is greater than a predetermined value with a positive slope or rate of change.

9. The method of claim 6 wherein the step of delivering a DF shock on the nth complex includes timing the shock based on when the amplitude of the VF

20 signal is greater than a predetermined value and has a positive slope or rate of change.

10. A method of treating ventricular fibrillation, comprising the steps of:

- monitoring a signal representative of ventricular electrical activity

25 during a period of ventricular fibrillation;

- detecting the occurrence of coarse VF complexes;
- analyzing coarse VF complexes to determine upslope; and
- delivering a DF shock during the upslope of the nth counted

30 complex, where n is a number greater than or equal to 2 and less than or equal to about 9.

11. A method according to claim 10 wherein the step of analyzing includes counting coarse VF complexes.
12. The method of claim 10 wherein the step of monitoring comprises monitoring the morphology signal, between proximal and distal shocking coils, of an endocardial lead, and wherein the step of delivering a DF shock includes applying a pulse of electrical energy to the endocardial lead.
13. The method of claim 10 wherein the steps of detecting and analyzing the occurrence of a coarse VF complex includes sensing when the amplitude of the VF signal is greater than a predetermined value with a positive slope or rate of change.
14. The method of claim 10 wherein the step of delivering a DF shock on the nth complex includes timing the shock based on when the amplitude of the VF signal is greater than a predetermined value and has a positive slope or rate of change.
15. A method of determining when to deliver a DF shock to a heart in ventricular fibrillation, comprising the steps of:
 - a) monitoring a signal representative of ventricular electrical activity during a period of ventricular fibrillation;
 - b) detecting the occurrence of coarse VF complexes as intervals of increase of the absolute value of the monitored signal; and
 - c) selecting the time for DF shock delivery based on when the absolute value of the monitored VF signal reaches a predetermined value during a period of increasing rate.
16. A method of determining when to deliver a DF shock to a heart in ventricular fibrillation, comprising the steps of:

- a) monitoring a signal representative of ventricular electrical activity during a period of ventricular fibrillation;
- b) measuring the amplitude of the monitored signal;
- c) determining the rate of change of the amplitude of the monitored signal; and
- 5 d) selecting the time for DF shock delivery based on the amplitude of the monitored signal, a predetermined value during fibrillation, and whether the rate of change of the amplitude is positive.

10 17. A method of claim 16 wherein the step of measuring includes repeated sampling of the monitored signal, and the step of determining rate of change includes comparing samples of the monitored signal over a small increment of time.

15 18. A method of treating ventricular fibrillation, comprising the steps of:
a) monitoring a heart signal representative of ventricular electrical activity;
b) detecting the presence of ventricular fibrillation
c) during VF, detecting the occurrence of coarse VF complexes by
20 measuring the monitored signal; and
d) for the nth coarse VF complex, where n is greater than or equal to 2 and less than or equal to 9, delivering a coordinated DF shock based on the a predetermined value for the amplitude of the monitored signal, and whether the amplitude has a positive the rate of change.

25

19. A method according to claim 10 further including the step of delivering at least one asynchronous DF shock if the VF is not terminated by the delivery of coordinated DF shocks.

30 20. A defibrillator, comprising:

a lead system for placement in electrical contact with the ventricle of the heart;

a sensing system, attached to the lead system for monitoring ventricular electrical activity, which detects the presence of VF, and during VF to detect

5 coarse VF complexes;


a DF control system for controlling delivery of DF shocks through the lead system to the ventricle, the control system responsive to the sensing system to deliver a DF shock when the sensed VF complex increases to a predetermined value with a positive rate of change.

10

21. The defibrillator according to claim 20 wherein the DF control system comprises a counting subsystem which counts the occurrence of VF complexes, and the DF control system delivers a DF shock coordinated with the nth coarse VF complex, where n is greater than or equal to 2 and less than or equal to about

15 9.

22. The defibrillator according to claim 21 wherein the DF control system delivers the coordinated shocks during an interval following onset of VF, and at least one asynchronous DF shock if the VF is not terminated by the coordinated 20 shocks.






FIG. 2




FIG. 3




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/13016

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61N1/39

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,4 202 340 (MIROWSKI) 13 May 1980 see column 9, line 36 - column 10, line 64 ---	15-17, 20-22
A	US,A,5 439 483 (VENTRITEX) 8 August 1995 see the whole document ---	15-17, 20-22
A	EP,A,0 347 708 (CARDIAC PACEMAKERS) 27 December 1989 see column 6, line 47 - line 58 ---	15-17, 20-22
A	WO,A,93 20888 (MEDTRONIC) 28 October 1993 see page 14, line 16 - page 24, line 3 ---	15-17, 20-22
A	US,A,4 949 719 (VENTRITEX) 21 August 1990 see the whole document ---	15,20
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

19 November 1996

Date of mailing of the international search report

29. 11. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentstaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl
Fax (+ 31-70) 340-3016

Authorized officer

Lemercier, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/13016

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,5 179 945 (CARDIAC PACEMAKERS) 19 January 1993 see the whole document ---	15,20
A	EP,A,0 550 343 (ELA MEDICAL) 7 July 1993 see the whole document ---	15,20
A	EP,A,0 550 344 (ELA MEDICAL) 7 July 1993 see the whole document -----	15,20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 96/13016

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-4202340	13-05-80	CA-A- CA-A- CA-A- DE-A- DE-C- GB-A- JP-C- JP-A- JP-B- NL-A- US-A-	1087691 1106920 1106921 2643907 2661005 1538522 1157743 52044089 57053108 7610831 4184493	14-10-80 11-08-81 11-08-81 07-04-77 08-03-90 17-01-79 25-07-83 06-04-77 11-11-82 01-04-77 22-01-80
US-A-5439483	08-08-95	NONE		
EP-A-347708	27-12-89	AU-A- JP-A-	3643189 2046823	21-12-89 16-02-90
WO-A-9320888	28-10-93	US-A- AU-B- AU-A- CA-A- EP-A- JP-T-	5312441 649177 3801293 2102493 0592625 6503506	17-05-94 12-05-94 18-11-93 14-10-93 20-04-94 21-04-94
US-A-4949719	21-08-90	AT-T- CA-A- DE-D- DE-T- EP-A-	119793 2013814 69017743 69017743 0395242	15-04-95 26-10-90 20-04-95 17-08-95 31-10-90
US-A-5179945	19-01-93	EP-A-	0568739	10-11-93
EP-A-550343	07-07-93	FR-A- DE-D- DE-T- ES-T- US-A-	2685624 69207573 69207573 2082415 5325856	02-07-93 22-02-96 20-06-96 16-03-96 05-07-94
EP-A-550344	07-07-93	FR-A- DE-D-	2685643 69210380	02-07-93 05-06-96

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 96/13016

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-550344		DE-T- 69210380 ES-T- 2088563 US-A- 5350406	05-09-96 16-08-96 27-09-94